Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Research | December 09, 2025 | December 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 09, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,833 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Tax withholding · Disposed 4,229 · Balance 47,833 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 4,375 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,375 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 9,412 | $641.50 | $6,037,798.00 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,872 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 16,579 | $52.03 | $862,605.37 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,705 Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $492.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000053 · edgardoc.xml · derivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-12-09 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000053 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,350 F2 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 9, 2022 and 50% on December 9, 2024. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 8,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000053 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,421 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on December 9, 2025. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 114 | $556.45 | $63,435.30 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 21 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,136 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · price: Represents volume-weighted average price of sales of 114 shares of Company stock on November 17, 2020 at prices ranging from $556.38 to $556.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 64 | $553.21 | $35,405.44 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 20 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,250 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 73 | $552.88 | $40,360.24 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 19 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,314 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 141 | $551.48 | $77,758.68 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 18 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,387 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 141 shares of Company stock on November 17, 2020 at prices ranging from $551.31 to $551.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 206 | $550.71 | $113,446.26 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 17 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,528 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 206 shares of Company stock on November 17, 2020 at prices ranging from $550.52 to $550.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 283 | $549.67 | $155,556.61 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 16 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,734 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 283 shares of Company stock on November 17, 2020 at prices ranging from $549.03 to $549.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 216 | $548.77 | $118,534.32 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 15 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,017 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 216 shares of Company stock on November 17, 2020 at prices ranging from $548.47 to $548.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 148 | $547.12 | $80,973.76 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 14 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,233 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 148 shares of Company stock on November 17, 2020 at prices ranging from $547.12 to $547.20. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 524 | $546.61 | $286,423.64 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,381 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 524 shares of Company stock on November 17, 2020 at prices ranging from $546.08 to $546.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 171 | $545.47 | $93,275.37 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,905 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 171 shares of Company stock on November 17, 2020 at prices ranging from $545.37 to $545.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 68 | $544.01 | $36,992.68 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,076 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 467 | $543.65 | $253,884.55 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,144 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 467 shares of Company stock on November 17, 2020 at prices ranging from $543.07 to $543.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 294 | $542.37 | $159,456.78 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,611 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 294 shares of Company stock on November 17, 2020 at prices ranging from $542.15 to $542.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 812 | $541.42 | $439,633.04 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,905 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 812 shares of Company stock on November 17, 2020 at prices ranging from $541.01 to $541.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,442 | $540.49 | $779,386.58 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,717 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 1,442 shares of Company stock on November 17, 2020 at prices ranging from $540.00 to $540.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 42 | $539.87 | $22,674.54 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,159 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 42 shares of Company stock on November 17, 2020 at prices ranging from $539.50 to $539.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 591 | $538.37 | $318,176.67 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,201 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 591 shares of Company stock on November 17, 2020 at prices ranging from $538.03 to $538.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 229 | $537.38 | $123,060.02 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,792 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 229 shares of Company stock on November 17, 2020 at prices ranging from $537.15 to $537.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 743 | $536.68 | $398,753.24 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,021 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 743 shares of Company stock on November 17, 2020 at prices ranging from $536.41 to $536.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2020 at each separate price. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,736 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · derivative · entry 23 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,736 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F18 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 7,108 | $561.39 | $3,990,360.12 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,764 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 13,736 | $30.63 | $420,733.68 |
DisclosureSEC source: 0001708138-20-000108 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,921 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001237899-20-000044 · edgardoc.xml · derivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,921 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,264 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001237899-20-000044 · edgardoc.xml · derivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,264 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,264 | $30.63 | $99,976.32 |
DisclosureSEC source: 0001237899-20-000044 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,921 | $52.03 | $99,949.63 |
DisclosureSEC source: 0001237899-20-000044 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 79 | $639.55 | $50,524.45 |
DisclosureSEC source: 0001708138-20-000088 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,951 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 239 | $638.96 | $152,711.44 |
DisclosureSEC source: 0001708138-20-000088 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,030 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 239 shares of Company stock on July 14, 2020 at prices ranging from $638.87 to $638.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 182 | $637.48 | $116,021.36 |
DisclosureSEC source: 0001708138-20-000088 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,269 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 182 shares of Company stock on July 14, 2020 at prices ranging from $637.19 to $637.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 175 | $635.46 | $111,205.50 |
DisclosureSEC source: 0001708138-20-000088 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,451 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 175 shares of Company stock on July 14, 2020 at prices ranging from $635.29 to $635.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 89 | $634.18 | $56,442.02 |
DisclosureSEC source: 0001708138-20-000088 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,626 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 95 | $633.02 | $60,136.90 |
DisclosureSEC source: 0001708138-20-000088 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,715 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 679 | $632.12 | $429,209.48 |
DisclosureSEC source: 0001708138-20-000088 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,810 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 679 shares of Company stock on July 14, 2020 at prices ranging from $632.04 to $632.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 578 | $631.32 | $364,902.96 |
DisclosureSEC source: 0001708138-20-000088 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,489 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 578 shares of Company stock on July 14, 2020 at prices ranging from $631.07 to $631.43. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 264 | $630.77 | $166,523.28 |
DisclosureSEC source: 0001708138-20-000088 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,067 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 852 | $629.58 | $536,402.16 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 30 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,331 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F24 · price: Represents volume-weighted average price of sales of 852 shares of Company stock on July 14, 2020 at prices ranging from $629.22 to $629.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. F25 · balance_after: Form one of two Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 950 | $628.50 | $597,075.00 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 29 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,183 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F23 · price: Represents volume-weighted average price of sales of 950 shares of Company stock on July 14, 2020 at prices ranging from $628.03 to $628.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 83 | $626.66 | $52,012.78 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 28 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,133 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $625.05 | $2,500.20 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 27 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,216 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 487 | $624.77 | $304,262.99 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 26 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,220 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F22 · price: Represents volume-weighted average price of sales of 487 shares of Company stock on July 14, 2020 at prices ranging from $624.38 to $624.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $622.51 | $622.51 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 25 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,707 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 113 | $621.06 | $70,179.78 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 24 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,708 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 81 | $620.94 | $50,296.14 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 23 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,821 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F21 · price: Represents volume-weighted average price of sales of 81 shares of Company stock on July 14, 2020 at prices ranging from $620.07 to $620.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 162 | $619.28 | $100,323.36 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 22 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,902 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F20 · price: Represents volume-weighted average price of sales of 162 shares of Company stock on July 14, 2020 at prices ranging from $619.01 to $619.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.